Navigation Links
Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimer's
Date:6/3/2009

Tampa, Florida (June 2, 2009) --Researchers affiliated with Natura Therapeutics, Inc., Tampa, Florida, and the University of South Florida (USF) have jointly received a one-year, $110,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health's (NIH) National Center for Complementary and Alternative Medicine to continue studying TeaMem, a compound made from green tea.

TeaMem holds promise for preventing and treating Alzheimer's disease (AD), a disease that the Alzheimer's Association says today affects as many as 5.2 million Americans. The most recent grant follows two other NIH grants to develop and evaluate TeaMem -- a $160,000 grant for 2007-2008 and a $140,000 grant for 2008-2009. The research conducted under these three grants was also supported through matching funds from the Florida High Tech Corridor Matching Grants Research Program.

According to Jun Tan, M.D., Ph.D., a professor in the USF Department of Psychiatry and Behavioral Medicine, and one of the grant's principal investigators, the grant will be used to investigate the role of TeaMem in opposition to cleavage of the amyloid precursor protein protelysis (APP) into Abeta peptides and resultant cerebral amyloidosis, a process identified as a key feature in AD pathology.

"Our recent findings suggest that strategies that promote non-amyloidogenic/alpha-secretase APP processing may have significant potential for the treatment of AD," said Tan.

This SBIR grant, the most recent of three NIH grants, allows the continuing development of TeaMem and its evaluation in the test tube (in vitro). The latest grant provides for testing in vitro and in the body (in vivo) using mouse models to evaluate the effects of TeaMem.

Early tests will evaluate TeaMem in promoting non-amyloidogenic APP alpha-secretase proteolysis and then examine its therapeutic and preventive effects on AD pathology and cognitive impairment.

"We expect to clearly define this non-amyloidogenic mechanism and identify the potential molecular drug targets essential for formulating novel, effective treatments against AD," explained Cyndy D. Sanberg, Ph.D., senior vice president of Natura Therapeutics, Inc. and the other PI on the grant.

Tests, including cognitive tests, will use mouse models for oral administration of TeaMem to a prophylactic treatment group that will be compared to a second group with AD-like pathology. Groups will be compared for the effect of reducing AD-like pathology and behavioral impairment. The studies, said Tan, could lay the groundwork for AD clinical trials in humans in the near future.

In their 2008 report, the Alzheimer's Association (www.alz.org) noted that AD was the nation's sixth leading cause of death and predicts 10 million baby boomers will develop AD. The direct and indirect costs of AD exceed $148 billion annually, said the Association.


'/>"/>

Contact: Dr. Jun Tan
jtan@health.usf.edu
813-974-9326
University of South Florida Health
Source:Eurekalert

Related medicine news :

1. The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally
2. The First High Performance Sports Water - AquaHydrate - to Offer Ionic Minerals Through Exclusive Agreement With Natural Foods Pioneer, Trace Minerals Research
3. New Journal of Natural Medicine Launched This June, Promotes Natural Therapy
4. Chocolate Milks Natural Muscle Recovery Benefits Match or May Even Surpass a Specially Designed Carbohydrate Sports Drink
5. Buster Brands Launches Natural Alternatives to Acetaminophen Pain Killers
6. US Farms, Inc. Announces Membership to Natural Products Association
7. Sun Shower(TM) All Natural Super Blends Now Light N Healthy
8. Introducing COPPERTONE(R) NutraShield(R) With Dual Defense(R), New Sunscreen Line With Antioxidants To Help Promote Natural Skin Repair
9. Natural Alternatives International, Inc. Announces Fiscal 2009 Q3 Results
10. Super Lice Repelled by All-Natural Products First Ever Independent Study Shows
11. When Stomach Flu Strikes, Work With, Not Against, Body's Natural Defenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 AVACEN Medical , Inc. (AVACEN) ... their  2017 New Product Innovation Award for Its fibromyalgia ... and secondary medical device market research by Frost & Sullivan,s ... OTC, drug-free pain relief product, the AVACEN 100, offers a ... fibromyalgia widespread pain. ...
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
Breaking Medicine Technology: